Inovio Plunges On Interim Phase 1 Coronavirus Data; DNA Vaccine Shows 94% Response Rate

Posted by Shanthi Rexaline

Share on Facebook

Tweet on Twitter

Inovio Pharmaceuticals Inc shares were moving to the downside Tuesday after the vaccine maker released interim Phase 1 data for the study that is evaluating its DNA vaccine against SARS-CoV-2, the virus that causes COVID-19.

Inovio’s Interim Phase 1 Efficacy, Safety Readouts: Announcing results from the first two cohorts of the Phase 1 trial, the Plymouth, Pennsylvania-based biotech said multiple immunology assays showed that 94% of participants demonstrated overall immunological response rates.

The readout includes humoral and cellular immune responses conducted for the 1 mg and 2 mg dose cohorts after two doses at week six…CLICK for complete article